Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Interventional × Fruquintinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2319 Carcinoma, Non-Small-Cell Lung 1881 Prostatic Neoplasms 1219 Colorectal Neoplasms 1074 Neoplasms 1040 Multiple Myeloma 905 Lung Neoplasms 864 Neoplasm Metastasis 842 Leukemia, Myeloid, Acute 821 Lymphoma 749 Melanoma 732 Pancreatic Neoplasms 693 Ovarian Neoplasms 673 Carcinoma, Hepatocellular 645 Recurrence 642 Stomach Neoplasms 633 Leukemia 627 Lymphoma, Non-Hodgkin 569 Leukemia, Lymphocytic, Chronic, B-Cell 552 Lymphoma, Large B-Cell, Diffuse 522 Squamous Cell Carcinoma of Head and Neck 517 Precursor Cell Lymphoblastic Leukemia-Lymphoma 502 Brain Neoplasms 502 Head and Neck Neoplasms 501 Glioblastoma 494 Carcinoma, Renal Cell 483 Rectal Neoplasms 480 Myelodysplastic Syndromes 442 Sarcoma 430 Lymphoma, Follicular 430

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡